My thoughts on what matters to MNK, page-13

Madam .... From MSB's perspective its about receiving the $$ and also partnering with a Pharma that is passionate about MPC's and also having capable distribution and sales team.

MNK is a $4.8bn mkt cap company with $3m bn sales turnover.

As you were not around at the time, let me help you understand that CEPH (Dec 2010) was a $3.5bn   mkt cap company with a $2.5bn turnover at the time. History will tell you CEPH paid $350M to Mesoblast in partnering Revacsor + cord blood ( plus $1.7bn on agreed milest0nes).

Here is an article at the time the deal occurred. Please read it for your own benefit.
http://www.genengnews.com/gen-news-...ialize-mesoblast-stem-cell-therapies/81244348

So given the similarities with CEPH ( a passionate and hungry Global Pharma) , in my view MNK would be an accomplished  and adept partner with the financial capacity to deliver for MSB ....

.....are we about to experience Dec 2010 all over again ?


GLTAH